VYGR · Insider Trading
Voyager Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by VYGR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | James A Geraghty | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Jude Onyia | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Catherine J Mackey | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Michael J Higgins | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Nancy Vitale | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Glenn Pierce | Director | A | +30,000 deriv. | — |
| 2026-06-11 | George A Scangos | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Steven Hyman | Director | A | +30,000 deriv. | — |
| 2026-06-11 | Grace Colon | Director | A | +30,000 deriv. | — |
| 2026-04-03 | Alfred Sandrock | President and CEO | Sell | −11,511 | −$44.55K |
| 2026-04-03 | Gregory L. Shiferman | SVP and General Counsel | A | +50,000 | — |
| 2026-02-26 | Alfred Sandrock | President and CEO | Sell | −14,197 | −$53.81K |
| 2026-02-26 | Robin Swartz | COO & CBO | Sell | −6,458 | −$24.35K |
| 2026-02-26 | Todd Alfred Carter | Chief Scientific Officer | Sell | −4,174 | −$15.69K |
| 2026-02-26 | Nathan D. Jorgensen | Chief Financial Officer | Sell | −4,668 | −$17.60K |
| 2026-02-20 | Todd Alfred Carter | Chief Scientific Officer | Sell | −3,301 | −$11.36K |
| 2026-02-20 | Alfred Sandrock | President and CEO | Sell | −11,732 | −$40.01K |
| 2026-02-20 | Robin Swartz | COO & CBO | Sell | −3,882 | −$13.35K |
| 2026-02-11 | Todd Alfred Carter | Chief Scientific Officer | Sell | −3,525 | −$13.57K |
| 2026-02-11 | Alfred Sandrock | President and CEO | Sell | −12,192 | −$46.09K |
| 2026-02-11 | Robin Swartz | COO & CBO | Sell | −4,569 | −$17.59K |
| 2026-02-10 | Robin Swartz | COO & CBO | A | +45,000 | — |
| 2026-02-10 | Alfred Sandrock | President and CEO | A | +86,250 | — |
| 2026-02-10 | Nathan D. Jorgensen | Chief Financial Officer | A | +32,250 | — |
| 2026-02-10 | Todd Alfred Carter | Chief Scientific Officer | A | +33,000 | — |
| 2026-02-10 | Toby Ferguson | Chief Medical Officer | A | +45,000 | — |
| 2026-01-08 | Gregory L. Shiferman | SVP and General Counsel | A | +100,000 deriv. | — |
| 2025-10-07 | Nathan D. Jorgensen | Chief Financial Officer | Sell | −7,666 | −$36.64K |
| 2025-08-20 | Toby Ferguson | Chief Medical Officer | Sell | −19,000 | −$70.87K |
| 2025-06-04 | Catherine J Mackey | Director | A | +24,000 deriv. | — |
| 2025-06-04 | Jude Onyia | Director | A | +24,000 deriv. | — |
| 2025-06-04 | Steven Hyman | Director | A | +24,000 deriv. | — |
| 2025-06-04 | Grace Colon | Director | A | +24,000 deriv. | — |
| 2025-06-04 | George A Scangos | Director | A | +24,000 deriv. | — |
| 2025-06-04 | Nancy Vitale | Director | A | +24,000 deriv. | — |
| 2025-06-04 | Glenn Pierce | Director | A | +24,000 deriv. | — |
| 2025-06-04 | Michael J Higgins | Director | A | +24,000 deriv. | — |
| 2025-06-04 | James A Geraghty | Director | A | +24,000 deriv. | — |
| 2025-04-04 | Alfred Sandrock | President and CEO | Sell | −10,885 | −$37.34K |
| 2025-04-04 | Toby Ferguson | Chief Medical Officer | Sell | −10,086 | −$34.59K |
| 2025-02-24 | Sandell Jacquelyn Fahey | Chief Legal Officer | A | +41,500 | — |
| 2025-02-24 | Nathan D. Jorgensen | Chief Financial Officer | A | +51,500 | — |
| 2025-02-24 | Toby Ferguson | Chief Medical Officer | A | +63,000 | — |
| 2025-02-24 | Alfred Sandrock | President and CEO | MIXED | +133,298 | −$49.62K |
| 2025-02-24 | Todd Alfred Carter | Chief Scientific Officer | MIXED | +42,695 | −$14.08K |
| 2025-02-24 | Robin Swartz | COO & CBO | MIXED | +67,356 | −$16.55K |
| 2025-02-12 | Todd Alfred Carter | Chief Scientific Officer | Sell | −5,413 | −$24.09K |
| 2025-02-12 | Robin Swartz | COO & CBO | Sell | −6,950 | −$30.93K |
| 2025-02-12 | Sandell Jacquelyn Fahey | Chief Legal Officer | Sell | −4,358 | −$19.39K |
| 2025-02-12 | Alfred Sandrock | President & CEO | Sell | −16,644 | −$74.07K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Alfred Sandrock | President and CEO | 472,549 | $1.16M |
| Robin Swartz | COO & CBO | 199,738 | $489.36K |
| Toby Ferguson | Chief Medical Officer | 183,914 | $450.59K |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 | $370.97K |
| Todd Alfred Carter | Chief Scientific Officer | 145,718 | $357.01K |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 | $301.70K |
| James A Geraghty | Director | 76,588 | $187.64K |
| Gregory L. Shiferman | SVP and General Counsel | 50,000 | $122.50K |
| Michael J Higgins | Director | 31,314 | $76.72K |
| Glenn Pierce | Director | 21,788 | $53.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VYGR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.